COMMUNIQUÉS West-GlobeNewswire

Jade Biosciences Announces $135 Million Private Placement
07/10/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
07/10/2025
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve [...]
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
07/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
07/10/2025
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
07/10/2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
07/10/2025
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and [...]
Parexel Expands Global Site Alliance Program, Delivering 40% Faster Site Activation, 20% Faster Study Start Up Timelines and Four Times More Patient Enrollments Per Site
07/10/2025
Parexel’s Site Alliance Program strengthens global partnerships with clinical research sites and reinforces leadership in site engagement excellence RALEIGH, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading [...]
Privia Health to Report Third Quarter 2025 Results on Thursday, November 6
07/10/2025
ARLINGTON, Va., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, [...]
Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®
07/10/2025
Nausea and Vomiting Are the Most Frequent Reasons for Discontinuing GLP-1 Therapies, Significantly Impacting Adherence, Titration and Preventing Achievement of Proven Long-Term Benefits WOBURN, Mass., Oct. 07, 2025 ( [...]
MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets
07/10/2025
MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc [...]
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
07/10/2025
MELBOURNE, Australia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing treatments for recurring and metastatic [...]
GATC Health Announces Launch of Derisq: The Definitive AI Report for Predictive Risk Assessment of Drug Candidates at Fierce Biotech Week 2025
07/10/2025
Derisq delivers actionable insights about drug safety, efficacy and off-target risks prior to committing development capital BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GATC Health, a leading tech-bio company leveraging [...]
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
07/10/2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc [...]
Prenetics Completes $72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8’s Path to $100 Million ARR
07/10/2025
Strengthens Balance Sheet with Over $60 Million in Cash 1 , Excluding Bitcoin Treasury David Beckham Co-Founded IM8 on Track to Achieve $100 Million ARR in First Year, Becoming One of the Fastest-Growing Supplement [...]
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
07/10/2025
FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for [...]
Clover Health to Report Third Quarter 2025 Financial Results on November 4, 2025
07/10/2025
WILMINGTON, Del., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company dedicated to bringing access to great [...]
Profusa Invests Additional $1 Million in Digital Treasury Assets
07/10/2025
BERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the [...]
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
07/10/2025
$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in [...]

Pages